Rituximab in the Treatment of B-Cell Non-Hodgkin Lymphoma, Focus on Outcomes and Comparative Effectiveness

ClinicoEconomics and Outcomes Research - New Zealand
doi 10.2147/ceor.s4221
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Regulation of CD20 in Rituximab-Resistant Cell Lines and B-Cell Non-Hodgkin Lymphoma

Clinical Cancer Research
Cancer ResearchOncology
2012English

Subcutaneous Rituximab in B-Cell Non-Hodgkin Lymphoma: A Single-Center Experience

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Autologous Stem Cell Transplantation Outcomes in Elderly Patients With B Cell Non-Hodgkin Lymphoma

British Journal of Haematology
Hematology
2015English

MicroRNA Dysregulation in B-Cell Non-Hodgkin Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy
2013English

Expression of PAX-5 in B Cell Hodgkin and Non Hodgkin Lymphoma

Asian Pacific Journal of Cancer Prevention
2018English

Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2014English

A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND Β-Glucan PGG IN RELAPSED/REFRACTORY INDOLENT B-Cell NON-HODGKIN LYMPHOMA

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

The Therapeutic Effectiveness of 177Lu-Lilotomab in B-Cell Non-Hodgkin Lymphoma Involves Modulation of G2/M Cell Cycle Arrest

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2019English

Choosing the Appropriate Salvage Therapy for B-Cell Non-Hodgkin Lymphoma

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy